
CAS 952652-79-8
:Sortieren nach
Reinheit (%)
0
100
|
0
|
50
|
90
|
95
|
100
8 Produkte.
Valsartan Related Compound B (N-butyryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]methyl}-L-valine)
CAS:Aromatic or modified aromatic drugs with nitrogen heterFormel:C23H27N5O3Farbe und Form:White PowderMolekulargewicht:421.21139Valsartan EP Impurity C (Valsartan USP Related Compound B)
CAS:Formel:C23H27N5O3Farbe und Form:Off-White SolidMolekulargewicht:421.50(2S)-2-[Butanoyl[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]amino]-3-methylbutanoic Acid
CAS:Farbe und Form:NeatValsartan n-Propyl Impurity
CAS:Kontrolliertes Produkt<p>Impurity Valsartan Related Compound B<br>Applications Valsartan n-Propyl is an impurity in the synthesis of Valsartan (V095750). Valsartan USP Related Compound B.<br>References Hillaert, S., et al.: J. Pharm. Biomed. Anal., 31, 329 (2003), Carlucci, G., et al.: Anal. Lett., 33, 2491 (2000), Cagigal, E., et al.: Talanta, 54, 1121 (2001),<br></p>Formel:C23H27N5O3Farbe und Form:WhiteMolekulargewicht:421.49N-(1-Oxobutyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
CAS:<p>N-(1-Oxobutyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine (GW1929) is a potent vasodilator that is used for the treatment of hypertension. It is synthesized by condensation of sodium hydroxide with 2-(4′-chlorophenyl)piperazine followed by methyl esterification and chloride acylation. The synthesis of GW1929 has been accomplished in two steps: carbonate cyclization and valsartan hydrolysis. In the first step, the carboxylic acid group of GW1929 was converted to its corresponding chloride compound which was then reacted with methyl bromide to yield the desired product. The second step involved hydrolysis of GW1929 with potassium carbonate, after which it was oxidized with azide to form an ester. Sodium</p>Formel:C23H27N5O3Reinheit:Min. 95%Farbe und Form:White PowderMolekulargewicht:421.49 g/mol







